Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNI-low dose Sandimmun Optoral plus Certican versus standard immunosuppression in renal transplant patients with creeping creatinine
2009-012200-98Phase 4Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus, cyclosporine and prednisolone (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Glomerular Filtration Rate. Started Sep 2010; status: terminated.
02
Drugs
everolimuscyclosporineprednisolone
Beyond the preview
Go deeper on 2009-012200-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012200-98.